SciBase Receives Additional Order from Castle Biosciences to Accelerate Atopic Dermatitis Relapse-Prediction Studies
核心洞察
SciBase received an additional order from Castle Biosciences (搜索) valued at approximately $0.6 million (MSEK 5) for portable Nevisense Go (搜索) pen devices and electrodes.
The order accelerates the ongoing clinical study and supports preparation for a second study under the companies' collaboration and license agreement established in 2025.
The collaboration aims to predict relapses in atopic dermatitis (搜索) (AD), with deliveries expected to begin in Q4 2026.
SciBase Holding AB (搜索) (STO: SCIB), a leader in AI-based devices for detection and prevention in dermatology, announced on September 8, 2026 that it has received an additional order from Castle Biosciences (搜索) (NASDAQ: CSTL) to accelerate an ongoing clinical study and prepare for a second clinical study under the two companies' collaboration. The order consists of the portable Nevisense Go (搜索) pen device and electrodes, valued at approximately $0.6 million, or roughly MSEK 5.
The collaboration and license agreement between SciBase and Castle Biosciences (搜索), a US-based leader in molecular diagnostics, was established in 2025. The first study under the collaboration project aims to predict relapses in atopic dermatitis (搜索) (AD) and is currently ongoing. The new order supports both an acceleration of this initial clinical study and preparation for a second clinical study, with deliveries expected to start in Q4 2026.
"The collaboration with Castle Biosciences (搜索) is moving forward at a fast pace with rapid patient recruitment in our first joint study and this additional order signals the expansion of our collaboration," said Pia Renaudin, CEO of SciBase. "At SciBase we are very excited to, together with Castle Biosciences, help patients with skin barrier dysfunctions get access to more effective therapies."
SciBase develops, manufactures, and commercializes Nevisense, a point-of-care platform that combines AI and advanced electrical impedance spectroscopy (EIS) technology to elevate diagnostic accuracy and support proactive skin health management. The company's technology is built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden.
The announcement was made public pursuant to the EU Market Abuse Regulation and was submitted for publication at 03:00 PM CEST on September 8, 2026.